MedTrace Logo

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

NCT06068465 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2026-02-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).

Conditions

  • Parkinson's Disease Psychosis

Interventions

DRUG

pimavanserin tartrate

pimavanserin tartrate, 34 mg, capsule, once daily by mouth for 6 weeks

DRUG

placebo

placebo, capsule, once daily by mouth for 6 weeks

Sponsors & Collaborators

  • Tasly Pharmaceutical Group Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Rui Liu · Tianjin Tasly Sants Pharmaceutical Co., Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-27
Primary Completion
2026-02-01
Completion
2026-02-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06068465 on ClinicalTrials.gov